RxDoctor Payments Data

Christopher Stellman, MD

Family Medicine · Oklahoma City, OKNPI 1538454863

Payments from drug & device makers

$2,452in general payments, 2019–2025

Across 203 payments — averaging $12.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$944
  • Pfizer$641
  • GSK$209
  • AstraZeneca$101
  • Boehringer Ingelheim$57
  • Novartis$55
  • plus $444 from 16 others

What the payments were for

  • Food & beverage$2,440100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,452 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$73,593
Medicare patients
241
Services billed
1,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$92,339
JardianceEmpagliflozin49$70,025
XareltoRivaroxaban66$65,842
OzempicSemaglutide40$41,819
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$18,973
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$17,515
Enoxaparin Sodium13$15,372
Tresiba Flextouch U-100Insulin Degludec11$13,549
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$8,758
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$7,236
PremarinEstrogens, Conjugated11$6,323
SymbicortBudesonide/Formoterol Fumarate17$4,193
Gabapentin184$3,424
Atorvastatin Calcium425$3,290
Levothyroxine Sodium317$3,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$641$98,66297 claims
Boehringer IngelheimJardiance$57$70,02549 claims
Johnson & JohnsonXarelto$26$65,84266 claims
Novo NordiskOzempic$51$41,81940 claims
GSKAnoro Ellipta, Trelegy Ellipta$209$36,48838 claims
AstraZenecaSymbicort$101$4,19317 claims
AbbVieSynthroid$944$78522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →